TLIK Stock Overview
TELES Aktiengesellschaft engages in the pharmaceutical business in Germany and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
TELES Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.99 |
| 52 Week High | €2.52 |
| 52 Week Low | €0.95 |
| Beta | 0.45 |
| 1 Month Change | -7.01% |
| 3 Month Change | -15.68% |
| 1 Year Change | -58.19% |
| 3 Year Change | -22.87% |
| 5 Year Change | 3.65% |
| Change since IPO | -99.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| TLIK | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0.5% | -1.8% | 1.8% |
| 1Y | -58.2% | -3.5% | 4.2% |
Return vs Industry: TLIK underperformed the German Healthcare industry which returned -3.5% over the past year.
Return vs Market: TLIK underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| TLIK volatility | |
|---|---|
| TLIK Average Weekly Movement | 7.1% |
| Healthcare Industry Average Movement | 6.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TLIK's share price has been volatile over the past 3 months.
Volatility Over Time: TLIK's weekly volatility has decreased from 20% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 51 | Sascha Knoche | www.teles.com |
TELES Aktiengesellschaft engages in the pharmaceutical business in Germany and internationally. It offers products for oncology, neurology, ophthalmology, hemophilia, and autoimmune and infectious diseases. The company was founded in 1983 and is headquartered in Berlin, Germany.
TELES Aktiengesellschaft Fundamentals Summary
| TLIK fundamental statistics | |
|---|---|
| Market cap | €6.73m |
| Earnings (TTM) | -€2.88m |
| Revenue (TTM) | €59.28m |
0.1x
P/S Ratio-2.3x
P/E RatioIs TLIK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLIK income statement (TTM) | |
|---|---|
| Revenue | €59.28m |
| Cost of Revenue | €55.95m |
| Gross Profit | €3.33m |
| Other Expenses | €6.21m |
| Earnings | -€2.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 27, 2024
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 5.61% |
| Net Profit Margin | -4.86% |
| Debt/Equity Ratio | -183.8% |
How did TLIK perform over the long term?
See historical performance and comparison